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Advances in sarcoma treatment are largely based on investigator-initiated, multicentric and interdisciplinary clinical trials. The
EU’s Good Clinical Practice Directive 2001/20/EC, eﬀective since 2004, was meant to harmonize the conditions for clinical tri-
als across Europe, but, instead, the challenge of initiating and running multinational, noncommercial clinical trials has become
greater than ever. Institutions participating in existing noncommercial Pan-European studies are struggling to cope with increased
administrative and ﬁnancial burdens, and few new studies are initiated any more. The aim of a conference entitled “Pan-European
Sarcoma Trials: Moving Forward in a Climate of Increasing Economic and Regulatory Pressure,” held in Stuttgart, Germany, 30
November–2 December 2006 as part of the European Science Foundation’s ECT-program, was not only to provide an overview of
currently active and planned multinational studies on osteo-, Ewing’s, and soft tissue sarcoma, but also to draw on areas of synergy
between various established sarcoma groups in Europe to deﬁne plausible survival strategies for collaborative, interdisciplinary,
patient-oriented research.
Copyright © 2007 Dorothe Carrle et al.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. BACKGROUND
Since 1 May 2004, the date from which institutions conduct-
ing clinical trials in EU member states were obliged to have
the laws and administrative procedures in place to comply
with Good Clinical Practice under EU Directive 2001/20/EC,
the challenge of instigating and running noncommercial
clinical trials has been greater than ever. Institutions per-
forming existing noncommercial European trials are strug-
gling to cope with the increased administrative and ﬁnancial
burden caused by the new legislation, and there is a real dan-
ger that the onerous set-up criteria combined with increased
costswillcausefewernewstudiestobeinitiated. Theseissues
were taken up in a conference initiated by the three sarcoma
study groups of the German Society of Paediatric Oncology
and Hematology, GPOH, organised by COSS, the Coopera-
tive Osteosarcoma Study Group with support from the Eu-
ropean Science Foundation ECT-Programme. Its title “Pan-
European Sarcoma Trials: Moving Forward in a Climate of
Increasing Economic and Regulatory Pressure” (Stuttgart,
Germany, 30 November–2 December 2006) served as motto
for more than two hundred investigators from 19 countries
who are—or aspire to be—involved in the day-to-day man-
agement and/or implementation of Pan-European clinical
trials at an institutional level who gathered in Stuttgart for a
mixture of plenum presentations and interactive discussion
sessions.
The aim of the conference was not only to provide an
overview of currently active and planned multinational sar-
coma studies (osteo-, Ewing’s, and soft tissue) in Europe, but
also to draw on areas of synergy between various established
sarcomagroupsinEuropetodeﬁneaplausiblesurvivalstrat-
egy and ensure that joined-up research continues in the fu-
ture.
2. FIRST SESSION—BRINGING QUALITY INTO
LIFE: VIEWS AND PERSPECTIVES IN
SARCOMA PATIENTS
The importance of taking into account not just survival data
in clinical trials but also the patient and his/her family’s per-
spective on quality of life was demonstrated during the qual-
ity of life session discussing diﬀerent approaches to evaluate
QOL data.
This session culminated in a tour of the poster exhibition
“Bringing Medicine to Life.” Proof of the relevance of this
topic and the impact of the presentation is best provided by
the fact that a full-page article on the art project was pub-
lished in Lancet Oncology [1].2 Sarcoma
3. SECOND SESSION—THE REGULATORY AND
ECONOMIC ENVIRONMENT FOR CLINICAL
TRIALS IN EUROPE
In the introduction to this session, S. Bielack, Stuttgart,
Germany (ECT-Project Leader, EURAMOS) outlined the
need for a collaborative approach in establishing and run-
ning international sarcoma trials. Using graphic examples,
hedemonstratedhowtherealityofmeetingtherequirements
to implement the EU-Directive 2001/20/EC at a German na-
tional level contradicts the good intentions of the politicians
and law makers to facilitate and support clinical research. He
emphasised that the practical consequences of implementing
the new legislation is a source of major concern, especially
with regard to legal, ﬁnancial, and workload aspects.
In her talk “Challenges presented by applying current
regulations to the day to day running of trials,” K. Pritchard-
Jones (Chairperson, SIOP Europe Clinical Trials Commit-
tee), London, UK, shared her insight into the impact of the
EU-Directive not distinguishing between commercial and
academic trials. During the discussion, it became clear that
due to the diversity of national interpretation of the legis-
lation and subsequently diﬀerent implementations of it into
national law, the Directive has not only plainly failed to har-
monise the conduct of clinical trials throughout Europe but
has also raised major obstacles for the continuance of inter-
national collaborations which have functioned well until this
point in time.
In presenting the regulators’ view of how the EU-Direct-
ive was implemented into national law in Germany, C. Stef-
fen, Bonn, Germany (Head, Clinical Trials and GCP Inspec-
tions Unit, Federal Institute for Drugs and Medical Devices)
gave examples of how as a consequence of having to apply
strict “one size ﬁts all” procedures to all clinical trials, his
institution is being ﬂooded with—in many cases needless—
SAE reports. This “overload” situation hinders intelligent
pharmacovigilance. Following Dr. Steﬀen’s presentation, the
urgentneedforanadaptationoftheregulatoryproceduresto
the diﬀerent needs encountered with diﬀerent types of trials
was discussed.
Inhistalk“InterpretationandimplementationofEUleg-
islation at the national level—the paediatric clinician’s per-
spective,” H. J¨ urgens, Muenster, Germany (Past-President,
German Society of Paediatric Oncology and Haematology
and Chairman of the EURO-Ewing trial) explained how the
conduct of clinical trials has contributed to the provision of
a guaranteed (best) standard of treatment in the care of in-
dividual paediatric cancer patients. In taking the audience
through a risk versus beneﬁt evaluation of the EU-legislation
anditsimplementationatanationallevel,hepresentedphar-
macovigilance and professionalisation of research as positive
eﬀects, but the huge bureaucratic and ﬁnancial burdens as
negative factors which constitute a major threat to the con-
tinueddeliveryofbestquality-standardcare.Inthelivelydis-
cussion which followed his risk/beneﬁt analysis, it emerged
that a formal centralisation and standardisation at the pro-
fessional society level might provide a possible partial solu-
tion to some problems.
Inhistalk“Licensingandavailabilityofstandarddrugsin
paediatric oncology—the TEDDY perspective,” P. Paolucci,
Modena, Italy (Chairmen, TEDDY (the Task Force in Eu-
rope for Drug Development for Young)) presented the cur-
rent situation from the angle of an organisation whose aim
is to build research capacity in the development of paediatric
medicines and promote the safe and eﬀective use of exist-
ing medicines in children. He stressed the clinical and ethical
importance of being able to evaluate paediatric drugs, par-
ticularly in view of the current situation with the oﬀ-label
use of many drugs, the lack of paediatric formulations, and
the risk of withdrawal from the market. He suggested diﬀer-
ent strategies in order to achieve quality, eﬃcacy, and safety
of paediatric drugs within these diﬀerent situations. He also
statedthatovercautiousregulationsformarketingauthoriza-
tion requirements counteract the original intention of pro-
tecting the interest of the patients and jeopardize the possi-
bilitytoprovideoptimumcare.Theneedtobuildonexisting
frameworks and work within a multilevel network was made
clear during the discussion.
In her talk “Coordination of funding at the Pan-Euro-
pean level—the EUROCORES ECT Programme,” M. Resni-
coﬀ, Strassbourg, France (Coordinator, EUROCORES ECT
Programme in Medical Sciences) provided a concise outline
of the structure and the aims of the EUROCORES ECT Pro-
gramme. She illustrated how the European Science Founda-
tion (ESF) provides a platform for its member organisations
in order to promote research at the European level.
The need for an ongoing dialogue between funders and
the researchers who implement Pan-European clinical trials
wasthekeypointtocomeoutofthetalk“Supportfromchar-
itable organisations in Germany” presented by F. Kohlhuber,
Bonn, Germany (Project Aid Directorate, Deutsche Kreb-
shilfe). He explained that the increased ﬁnancial and ad-
ministrative burden as a consequence of the implementa-
tion of the EU-Directive accounts for the expanding gap be-
tween a limited funding budget and the requirements of re-
search, therefore contributing to a decline in the number of
investigator-initiated clinical trials.
In the roundtable discussion, “Balancing the needs of
patient-orientated clinical research with the demands of the
regulatory environment,” the regulatory obstacles to eﬀec-
tivePan-Europeancollaborationswithinthevarioussarcoma
groups were discussed. It transpired that—depending on
how the EU-Directive has been implemented on a national
level—the new legislation has resulted in both facilitating
and restricting research, with various degrees of complex-
ity. The discussion then focused on exploring solutions for
unresolved issues such as the legal requirement of sponsor-
ship. It was agreed that diﬀerent national interpretations of
the Directive should not hinder Pan-European collaboration
on randomised trials, nor obscure the achievement and on-
going need for ensuring a guaranteed standard of care. This
was considered especially important in rare diseases, where
randomised trials are not feasible. The responsibility of the
health insurance companies to prevent a decline in the qual-
ity of standard care was also discussed. During this lively and
attimesheateddiscussion,itbecameclearthatthesessiononDorothe Carrle et al. 3
the regulatory and economic environment had been a mu-
tual learning experience which had provided an excellent op-
portunitytogainnewinsightsintotheperspectivesofothers.
4. THIRD SESSION—OSTEOSARCOMA
The aim of this session was to update the participants of the
conference with recent results from multinational trials on
the most frequent of the bone sarcomas, to give an update
about the current status of the Pan-European/Transatlantic
EURAMOS study, to explore ways of expanding the EUR-
AMOS-networktoadditionalEuropeancountries,andtode-
velop and foster links with other European bone tumor net-
works, such as EuroBoNet.
Skipmetastasesarenotassociatedwithadismalprognosis,
L.Kager,Vienna,Austria
The prognostic implication of skip metastases in osteosar-
coma was retrospectively analysed in patients registered in
the neoadjuvant Cooperative Osteosarcoma Study Group
studies. It was shown that synchronous regional bone metas-
tases (skip metastases) are rare in osteosarcoma, and pre-
operative detection relies on appropriate diagnostic imag-
ing. Previously it was believed that patients with skip metas-
tases had an extremely poor prognosis. There, it was shown
that aggressive multimodal therapy holds the promise to
achieve prolonged survival, especially in patients in whom
these metastases occur within the same bone as the primary
lesion and whose tumors respond well to chemotherapy [2].
Doseintensityinosteosarcomatherapy:doesitmatter?
COSS:resultsfromaretrospectiveanalysisof917patients,
S.Bielack,Stuttgart,Germany
The possible prognostic relevance of dose intensity in the
treatment of osteosarcoma according to several consecutive
COSS protocols was retrospectively analysed. In an overall
setting of intensive multidrug treatment of osteosarcoma, it
could not be proved that a higher dose intensity correlated
with better outcomes [3].
EOI:resultsfromaprospectivetrialofdoxorubicin/cisplatin
+/−G-CSF,I.Lewis,Leeds,UK
The analysis of EOI data did not show a survival beneﬁt for
increasing received dose or dose intensity in the context of
a two-drug regimen with cisplatin and doxorubicin. The hy-
pothesis that increasing dose intensity may improve survival
inosteosarcomacouldnot beproven. Therewasnoclearevi-
dence of preoperative dose or dose-intensity inﬂuencing his-
tologic response [4].
UpdatedresultsoftheprospectivemulticentertrialCOSS-96,
S.Bielack,Stuttgart,Germany
Evaluation of a risk-adapted osteosarcoma chemotherapy
was the aim of the COSS-96 trial. A four-drug chemother-
apy was found highly eﬀective against osteosarcoma. Addi-
tional ﬁndings were that a long treatment duration may be
needed even for presumed low-risk patients. The outcome of
high-risk patients remained poor despite salvage treatment.
COSS-96 led the COSS group to realize that international
c o l l a b o r a t i o no nam u c hb r o a d e rl e v e lw o u l db er e q u i r e dt o
explore questions such as the potential role of salvage regi-
mens for osteosarcoma and formed the basis for the group’s
commitment to ECT-EURAMOS [5].
TheEuropeanandAmericanosteosarcomastudy
EURAMOS-1,M.Sydes,London,UK,D.Carrle,Stuttgart,
Germany,J.Whelan,London,UK,S.Smeland,Oslo,Norway
N.Marina,Stanford,USA,S.Bielack,Stuttgart,Germany,
A.Zoubek,Vienna,Austria,A.Holliday,London,UK,J.Stary,
Prague,CzechRepublic,W.Wozniak,Warsaw,Poland
The recruitment update from the coordinating data center
and progress reports from the collaborating groups COSS,
EOI, SSG, and COG were followed by brief reports on spe-
cial national issues of the participating countries. It emerged
that progress was made in that a big Swiss medical oncology
centermanagedtoresolvethenon-faultinsuranceissue,oth-
erwise an ongoing issue in Switzerland. Thanks to their huge
eﬀorts, the paediatric oncologists in Austria ﬁnally overcame
the sponsorship issue—an issue still unresolved for the non-
paediatric Austrian oncologists. Requests for participation in
EURAMOS from other groups and countries have resulted
in the production of an application procedure for applicant
countries,whichwaspresented.EURAMOSwaspresentedas
an example of a well-functioning Pan-European and Ameri-
can collaboration, while allowing space to maintain the indi-
vidual proﬁle of each collaborating study group.
EURAMOSnetworkingamongstosteosarcomagroups
EURO-B.O.S.S.:standardisedtreatmentforolderpatients
withosteosarcoma,S.Ferrari,Bologna,Italy
The outline and preliminary results of a collaborative project
involving the three European study groups ISG, SSG, and
COSS for patients over 40 years with osteosarcoma and other
spindle cell bone sarcoma were presented.
TheEuropeanRelapsedOsteosarcomaRegistry(EURELOS),
C.Int-Veen,Stuttgart,Germany
EURELOS, a much needed database for relapsed osteosar-
coma, another collaboration project between ISG, SSG, and
COSS has recently started recruitment.
Networkingclinicalosteosarcomatrialswith
basicresearchintheEuroBoNetworkpackage,H.B¨ urger,
Muenster,Germany
EuroBoNet (European network to promote researchinto un-
common cancers in adults and children: pathology, biol-
ogy, and genetics of bone tumours network of excellence)
is a collaborative programme intended to contribute to ob-
taining molecular portraits of bone tumours and to allow4 Sarcoma
investigations of speciﬁc hypothesis-driven approaches. This
would lead to further understanding and identiﬁcation of
markersformalignanttransformationand/orprogression,as
well as identiﬁcation of therapeutic targets. It is a powerful
instrument intended to overcome the fragmentation of the
Europeanresearchlandscapewiththeobjectivetostrengthen
European excellence and combine multidisciplinary exper-
tiseofpathologist,biologists,andoncologist.Majorgoalsare
integration, dissemination of knowledge, and excellence in
combined research. The EURAMOS group was called upon
to support this eﬀort by networking with EuroBoNet, for ex-
ample by providing tumour samples for expression array re-
search.
5. FOURTH SESSION—INTERGROUP PROJECTS
AND STRATEGIES
Pharmacovigilanceinsarcomatrials,T.Butterfass-Bahloul,
Muenster,Germany
Through the process of establishing a functioning pharma-
covigilance report system, the EURAMOS intergroup safety
desk has gained valuable experience which was shared in or-
der to serve other groups in setting up their own safety re-
porting systems. The complexities associated with the estab-
lishment of a Pan-European safety desk became obvious, ar-
guing for centralisation of such eﬀorts and networking be-
tween trials.
Assessingqualityoflifeinsarcomatrials,G.Calaminus,
Duesseldorf,Germany
The diﬀerent aspects of quality of life assessment in sarcoma
patients were presented. EURAMOS might serve as a model
for how to integrate a quality of life assessment project into a
trial aiming to optimise treatment strategies in sarcomas.
Functionalimpactofsurgeryonsarcomapatients,C.Gebert,
Muenster,Germany
C. Gebert gave a concise overview on the current surgical
approaches for sarcomas and explored if the functional out-
come of surgery is determined by the tumour rather than by
the surgical method.
Stateoftheartinsurgicaltherapyoflungmetastases,
K.Diemel,Grosshansdorf,Germany
The surgical management of pulmonary metastases with its
opportunities and pitfalls were presented in an illustrative
waywhichhelpedtoraiseawarenessofanadequateapproach
for the local treatment of pulmonary metastases.
ComparisonoftreatmentconceptsforextraosseousEwing’s
sarcomabetweensoft-tissueandbonesarcomatrials,
R.Ladenstein,Vienna,Austria
An analysis of the therapeutic strategies for extraosseous Ew-
ing’s sarcomas within two German Society of Paediatric On-
cology and Haematology (GPOH) Cooperative Study Group
concepts identiﬁed favourable disease factors, limits of the
analyses being diverging approaches with regards to tumor
assessment and to therapy.
Late-effectssurveillancesystem(LESS),M.Paulides,
Erlangen,Germany
Results of a prospective study on late eﬀects, performed in
thecontextofafollow-upnetworkforsarcomapatients,were
presented. The network was set up in order to standardise
and optimise the follow-up and to register major sequelae
with simple and sensitive methods.
Resultsofpilotstudieswereintegratedintothefollow-up
programs used by EURAMOS-1 and other current sarcoma
trials.
6. FIFTH SESSION—SOFT-TISSUE SARCOMA
EuropeanchallengesinestablishingaPan-European
protocolforrhabdomyosarcoma,M.Stevens,Bristol,UK
ImplementationofEuropeanregulationsatanationallevel:
barrierstoestablishingaPan-Europeanprotocolfor
localisedrhabdomyosarcoma,E.Koscielniak,Stuttgart,
Germany
TheobviousadvantagesofconductingtrialsinEuropeancol-
laborative networks (similar as for EURAMOS-1, faster re-
cruitment of patients, faster therapeutic progress, and im-
proved cooperation and networking between trial groups)
wasoutlined.Howeverthechallengesassociatedwiththeim-
plementation of the EU-Directive 2001/20/EC jeopardize the
conduction of a joint intergroup study.
Adjuvantchemotherapyinsynovialsarcomaandother
non-RMSsoft-tissuesarcoma:ayettoberesolved
controversialquestion,I.Brecht,Stuttgart,Germany
Outcomes in young patients with synovial sarcoma treated
withintensivemultimodal therapyappeartobeverypromis-
ing. It was described that it is only possible to learn more
about important treatment questions, for example, the role
of adjuvant chemotherapy, in uncommon diseases as non-
RMS soft-tissue sarcoma in multinational studies—simply
due to the rarity of these tumours in young patients [6].
Treatmentofmetastaticsoft-tissuesarcomawithintheCWS
group.ResultsoftheCWS-96IVstudy,T.Klingebiel,Frankfurt,
Germany
In this trial, maintenance chemotherapy appeared to lead to
better results than high-dose chemotherapy with stem-cell
rescue. The presentation showed that not only will the cur-
rent standard treatment of children with soft-tissue sarcoma
suﬀer if collaborative intergroup studies are impossible, but
exciting new developments such as metronomic treatment
may not be tested further in randomised trials too.Dorothe Carrle et al. 5
Resultsoftherandomisedstudyforlocalised“high-risk”
rhabdomyosarcoma.ReportoftheCWS-96andICG-96
studies,T.Dantonello,Stuttgart,Germany
The cooperative trials CWS-96 and ICG-96 were presented
as examples for a potential solution in the current situation
forEuropeansoft-tissuesarcomatrials:itmaybenecessary—
and this is certainly not ideal—to return to the level of net-
working and cooperation achieved in the 1990s: the carrying
out of diﬀerent randomised studies according to a consensus
about standard treatment with the use of similar stratiﬁca-
tions. It was stressed that this is by no means an ideal solu-
tion, but it is at least better than bringing studies to a halt.
Innovativeradiationmethodsandtheirrolein
thetreatmentofchildrenwithsoft-tissuesarcoma,
A.Schuck,Muenster,Germany
Diﬀerentinnovativeradiationtechniques(e.g.,protonbeam,
intensity-modulated, stereotactic) with their individual pros
and cons were described. It emerged that these new meth-
ods may be useful especially for children with soft-tissue sar-
coma due to the young age and sensitive involved sites of the
aﬀected patients. It will however be necessary to give these
techniques opportunities to evaluate them further in larger
cohorts.
HowtorealisecommonEuropeanbiologicalresearch
projectsforsoft-tissuesarcomawithintheEuropean
Soft-TissueSarcomaStudyGroup,A.Rosolen,Padova,Italy
The challenges in the realisation of common European bi-
ological research projects in soft-tissue sarcoma were ex-
plained. Basically, they resemble those of the EuroBoNet, but
there is currently no ﬁnance for setting-up a similar struc-
ture.
Clinicalrelevanceofmoleculardiagnosisin
rhabdomyosarcoma.RetrospectiveanalysisoftheCWS
studies,S.Stegmaier,Stuttgart,Germany
The largest analysis to date regarding the prognostic impact
of diﬀerent fusion types in alveolar rhabdomyosarcoma was
presented. It was explained that soft-tissue sarcomas oﬀer
interesting molecular research options due to the frequent
genetic alterations in these tumours and it would therefore
be regrettable if these research opportunities would not be
utilised. It was shown how previous studies in smaller sam-
ples lead to wrong conclusions. Thus, due to the relative rar-
ity and heterogeneity of these diseases, meaningful biologic
research projects require Pan-European cooperation.
6.1. Discussionandsummary
In the session on soft-tissue sarcoma, it became clear that the
problem scenario outlined by Kathy Pritchard-Jones in her
talk “Challenges presented by applying current regulations
to the day-to-day running of clinical trials” is already real-
ity which is threatening the eﬃcacy, motivation, and long-
term survival of established and experienced European sar-
coma groups. This predicament is primarily due to diﬀerent
implementations of the clinical trials directive at the individ-
ual country level; while some countries have interpreted the
legislation to mean that noncommercial academic trials and
trials prescribing the currently best available treatment do
not have to meet the same compliance criteria as industry-
sponsored studies investigating new drugs, others have inter-
preted it to mean that one should not distinguish between
academic and commercial trials at all.
The participants of the meeting were in full agreement
that if paediatric cancer patients were to be treated outside
clinical trials, the standard of care and the cure rate would
suﬀer. This is particularly valid in a group of very hetero-
geneous and complex diseases like paediatric soft-tissue sar-
coma, which frequently aﬀect very young children and ex-
pose them to intense multimodal treatment.
The relevance of the European soft-tissue sarcoma
group’s problems in overcoming the regulatory hurdles set
up by the current European legislation is emphasized by the
fact that the experience with the planned Pan-European soft-
tissue sarcoma trial was highlighted in recent articles from
Nature Medicine, which focused on the situation of clinical
trials in Europe [7, 8].
7. SIXTH SESSION—EWING’S SARCOMA
Basicrequirementsintheconventionalpathologicworkupof
Ewingtumours,responseevaluation,G.K¨ ohler,Muenster,
Germany,andP.Hogendoorn,Leiden,TheNetherlands
In a clear and concise presentation, the requirements of the
pathologic workup essential for diagnosis and response eval-
uation were summarized.
Currentinitiatives,targetsandmarkersinEwing’ssarcoma
biology,H.Kovar,Vienna,Austria
It was explained how urgently reliable prognostic markers
and novel targeted treatment approaches are required in Ew-
ing tumors. Possible ways of how these markers and targets
could be identiﬁed were presented with regard to lab inves-
tigation and collaborative research in European community
funded initiatives focussing on Ewing’s sarcoma. It was chal-
lenged that overlaps should be avoided in the diﬀerent initia-
tivesandhowpotentialsynergiescouldbeused.Intermediate
results from the accompanying biological studies in the on-
going EURO-Ewing trial and the lessons to be learned from
these projects were demonstrated.
EICESS92—Globalresultsandresultsaccordingtolocal
therapy,J.Whelan,London,UK
The results of the collaborative EICESS trial as example of
a large international trial in a rare disease were presented,
showing that there was no diﬀerences in the randomised
treatment arm with regard to overall survival. The diﬀer-
ent treatment approaches within the participating groups of
theintergrouptrialresultinginmoderatesurvivaldiﬀerences6 Sarcoma
were highlighted. The trial showed that a greater use of
surgery was associated with survival advantages and stressed
the standardisation of local treatment.
EICESS92—Resultsaccordingtoageandinstitution,
M.Paulussen,Basel,Switzerland
The previously divergent results of potential advantages of
treatment of adolescents/young adults according to paedi-
atric protocols were illustrated. The EICESS 92 trial as uni-
form protocol for children, adolescents, and adults provided
a unique opportunity to study outcomes according to age
and institution. It showed less diﬀerences between paedi-
atric and nonpaediatric institutions as compared with pre-
vious studies and no diﬀerences any longer in patients with
localised disease.
InterimreportonEURO-E.W.I.N.G.99,H.J¨ urgens,
Muenster,Germany
EURO-E.W.I.N.G.99 is a Pan-European intergroup trial ini-
tiated long before any attempt to harmonise GCP regula-
tionsacrossEurope.AsofOctober2006,nearly2000patients
could be recruited into the trial and randomisation compli-
ance was still improving. Recruitment thus currently exceeds
the expected numbers in all treatment arms. Final results are
yet to be awaited due to the ongoing nature of the trial, but
response to neoadjuvant chemotherapy seems to be superior
to the previous CESS and EICESS studies.
EURO-E.W.I.N.G.99—R3results,R.Ladenstein,
Vienna,Austria
Results of the treatment arm for Ewing tumours with metas-
tases to bone, bone marrow, and multifocal sites were pre-
sented, stressing the role of the various high-dose treatments
and the continuously poor prognosis for these patients.
Ewingtumoursininfants,H.vandenBerg,Amsterdam,
TheNetherlands
The treatment results of 14 infants with Ewing’s sarcoma
treated in one of the consecutive CESS, EICESS, and EURO-
E.W.I.N.G.99s trials were presented, demonstrating that—in
contrast to the literature—the majority of tumours were pP-
NET, the sarcomas were entirely axial, and overall survival
was comparable to older children.
ThevalueofFDG-PETinstagingandresponseevaluation,
U.Dirksen,Muenster,Germany
The value of PET in Ewing sarcoma staging and its possi-
ble role for evaluation of response as new prognostic marker
wereexplainedwithemphasisontheneedtoconductfurther
studies in this topic. Already now, the role of PET scans is es-
tablished in Ewing’s sarcoma due to its superior sensibility in
detecting bone lesions compared to classic bone scans [9].
Thevalueoftreosulfaninthetreatmentofhigh-riskEwing
tumours,U.Dirksen,Muenster,Germany
The role of treosulfan in cancer treatment was reviewed, and
promising results of a study exploring its use in paediatric
patients weredemonstrated.Treosulfanshowshighcytotoxic
activity against Ewing cells and may be a promising agent,
but its eﬃcacy regarding the treatment of Ewing’s sarcoma
currently remains to be proven. The safety proﬁle of treosul-
fan is however acceptable.
7.1. Discussionandsummary
The EURO-E.W.I.N.G. study started in 1999 and is still on-
going. It was explained that the trial has recently been pro-
longed to achieve the expected patient numbers in certain
subgroups and that the study was only possible in the ﬁrst
place because it was started prior to the implementation of
EU-Directive 20/2001/EC. It became clear during the discus-
sionthatratherthanfacingthearduousstrugglewiththebu-
reaucracy associated with the Directive, researchers are seek-
ing to prolong existing studies. While this is understandable,
these prolongations could well be regarded as a deceleration
of clinical research.
8. CONCLUSIONSAND RECOMMENDATIONS
FOR FURTHER ACTION
Initiated by the ECT-EURAMOS group and lead by COSS,
sarcoma study groups from across Europe gathered in
Stuttgart to share scientiﬁc knowledge, to intensify their
Pan-European and Transatlantic collaboration, and to ap-
proach the administrative, regulatory, and ﬁnancial chal-
lenges brought along with the European Clinical Trials Di-
rective.
The concept of stepping out of the scientiﬁc community
and approaching representatives from governments, regula-
tory authorities, and funding organisations in order to em-
phasize commonchallengesandtodiscussconstructivesolu-
tions proved successful. Coverage regarding both the session
on the regulatory and economic environment for clinical tri-
als in Europe meeting itself [10] and the speciﬁc problems of
establishing a Pan-European paediatric soft-tissue sarcoma
study under legislation driven by EU-Directive 2001/20/EC
(discussed at the meeting, see above, second and ﬁfth ses-
sions, highlighted in Nature Medicine [7, 8]) can be seen as
direct proof of the raised awareness through this meeting.
The intensive discussion resulted in an input on the
“Draft guidance on “speciﬁc modalities” for noncommer-
cial clinical trials referred to in Commission Directive
2005/28/EC laying down the principles and detailed guide-
lines for good clinical practice” by SIOP Europe [11]. The
conference also facilitated the exchange of ideas and experi-
ences and allowed for synergic eﬀects. For example, the ef-
fort put in the development of a meanwhile well-established,
well-functioning,internationallyrecognizedGCP-conformal
pharmacovigilance system resulted in recognizing it as a
model for other groups. The awareness that treatment out-
side clinical trials will lead to a decline in cure rates,Dorothe Carrle et al. 7
particularly in a group of very heterogeneous and complex
d i s e a s e ss u c ha ss a r c o m a s ,w a sw e l lp e r c e i v e d .I nr a r es a r -
coma subtypes, where prospective, randomised clinical trials
are unfeasible due to lack of numbers, alternative intergroup
strategies need to be pursued.
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